Life Sciences

The entire Life Science Industry is under pressure from generics, price controls, and weak drug pipelines. The industry is driven by:

	Increased FDA and global compliance requirements
	Strong pressure to reduce costs
	Economic Downturns
	Inefficient and ineffective management of acquisitions, alliances, partnerships, and licensing
	Counterfeit products resulting in significantlost revenue
	FDA/Agency delays in regulatory approvals

A rapidly changing business ecosystem, growing data volumes, pace of technology redundancy, and volatility in compliance requirements compound these challenges.

How to reduce the time and effort in getting a drug to the market is a challenge that is being heard in boardrooms and laboratories across the Healthcare and Life Sciences industry. More and more companies are attributing their progression in clinical trials and to product launches to the way they have integrated IT into the drug discovery and clinical trial processes. Enabling tools in the areas of Electronic Medical Record (EMR), Healthcare Information System, Sequence Analysis and Telemedicine have ensured that IT efforts are focused and aligned with business objectives.